FUJIREBIO
Fujirebio Europe and Self-screen B.V. today announced an expansion of their commercial collaboration with the distribution of the PreCursor-M AnoGYN methylation-specific molecular assay from Self-screen B.V. The test is intended for the detection of promoter hypermethylation of the genes ASCL1 and ZNF582 and is used to test the methylations status of anal specimens for research use only (RUO). It complements Fujirebio's HPV-associated molecular test portfolio.
“The Human Papilloma Virus (HPV) test panel of Fujirebio Europe continues to grow with effective and accurate testing solutions, and we are pleased to add this new RUO methylation-based assay to our molecular testing toolbox,” says Christiaan De Wilde, CEO at Fujirebio Europe “With its unmatched accuracy and reliability, this innovative PreCursor-M AnoGYN assay represents a significant advancement for research studies in the field of anal cancer prevention. We wanted our customers to have access to this valuable research tool as soon as possible, ultimately catalyzing advancements in elimination of HPV-related diseases.”
“We are very happy with the continued partnership with Fujirebio in the distribution of Self-screen’s HPV tests and methylation tests,” says Michelle Meijer, Chief Commercial Officer at Self-screen B.V. “The PreCursor-M AnoGYN extends our offering of HPV products into the field of anal cancer. Also in this HPV-related cancer, methylation appears to be promising for future use as an accurate biomarker for objective risk stratification of anal lesions. The growing medical need for better and more supportive diagnostics tools for HPV related cancers such as anal cancer drove us to the development of the PreCursor-M AnoGYN RUO assay which is now available through Fujirebio.”
About host cell DNA methylation and anal cancer
Incidence of anal cancer is increasing worldwide. The majority of anal cancers are squamous cell carcinoma (SCC) and are, like cervical cancer, mainly caused by a persistent high-risk HPV infection and preceded by high-grade squamous intraepithelial lesion (HSIL). In analogy with cervical cancer screening, the screening and treatment of HSIL to prevent anal cancer in high-risk groups are under debate. Host cell DNA methylation is an epigenetic hallmark of HPV-induced carcinogenesis. The PreCursor-M AnoGYN assay is a robust and reliable tool to further investigate host cell DNA methylation in anal carcinogenesis and study its potential as a valuable biomarker for the detection of anal (pre-)cancer.1-4
Please contact Fujirebio for further information about the local availability of the test.
About Self-screen B.V.
Self-screen B.V. is a company highly experienced in translational HPV related research, assay development and commercialization of In Vitro Diagnostics (IVD).
Our dedication is towards the development and clinical application of molecular assays for the early detection of anogenital and head & neck (pre)cancers, to the benefit of patients and health care programs around the world.
Our main focus is on cervical (pre)cancer screening and prevention. Self-screen markets two clinically validated CE-IVD assays. The HPV-Risk-Assay and the PreCursor-M+ Methylation Test, for screening and triage respectively, to support full molecular cervical screening and to assist the clinician in management of women with high-grade CIN. Recently PreCursor-M AnoGYN RUO is added. For more information, visit www.self-screen.nl.
About Fujirebio
Fujirebio is a global leader in the field of high-quality IVD testing. We have more than 50 years’ accumulated experience in the conception, development, production, and worldwide commercialization of robust IVD products.
Fujirebio has a long-lasting tradition for developing high-quality routine and truly novel biomarkers. Our IVD product lines span the range from specialized manual and automated testing to fully automated routine clinical laboratory testing solutions covering a variety of disease states.
Our global presence includes offices in the United States, Latin America, Europe and Asia as well as a vast international distribution network. For more information, visit www.fujirebio.com.
References:
- van der Zee R.P. , et al. Host cell deoxyribonucleic acid methylation markers for the detection of high-grade anal intraepithelial neoplasia and anal cancer. Clin. Infect. Dis., 68 (7); 1110-1117, 2019
- van der Zee R.P. , et al. Cancer risk stratification of anal intraepithelial neoplasia in human immunodeficiency virus-positive men by validated methylation markers associated with progression to cancer. Clin. Infect. Dis., 72 (12); 2154-2163, 2021
- van der Zee R.P. , et al. DNA methylation markers have universal prognostic value for anal cancer risk in HIV-negative and HIV-positive individuals. Mol. Oncol., 15 (11); 3024-3036, 2021, 2021
- Rozemeijer K, et al. Analytical validation and diagnostic performance of the ASCL1/ZNF582 methylation test for detection of high-grade anal intraepithelial neoplasia and anal cancer. Tumour Virus Res. 30;17:200275, 2023
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240304661911/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OPEX® Corporation Announces Key Enhancements to Infinity® Automated Storage and Retrieval System18.2.2025 10:00:00 CET | Press release
OPEX® Corporation, a global leader in Next Generation Automation providing innovative solutions for warehouse, document and mail automation, is introducing significant enhancements to its Infinity® Automated Storage and Retrieval System (AS/RS). Enhanced features include a 15 percent increase in the system’s storage payload, along with new storage slotting capabilities. The Infinity AS/RS, launched in 2022, combines unparalleled storage density, configurability and flexibility to meet the most pressing warehouse automation challenges in micro-fulfillment, omni-channel distribution, store replenishment and ecommerce. While the Infinity system was previously capable of supporting 70-pound (31.7 kilogram) payloads, the enhanced system can support 90-pound (40.8 kilogram) payloads. In addition to Infinity iBOT robots now supporting the increased payload, the racking structure, also known as the storage grid, has been updated to manage the increased weight, as well. “The decision to increas
Galderma’s Nemluvio® (Nemolizumab) Granted Marketing Authorization in the United Kingdom and Switzerland for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis18.2.2025 07:00:00 CET | Press release
These are the first approvals of nemolizumab from countries within the Access Consortium framework, with regulatory review processes ongoing in the remaining countries – Australia and Singapore Nemolizumab, which is also approved in the EU and U.S., is the first approved monoclonal antibody that specifically targets IL-31 receptor alpha, inhibiting the signaling of IL-31 – a neuroimmune cytokine that drives itch and other symptoms in both moderate-to-severe atopic dermatitis and prurigo nodularis1-6 Galderma today announced that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency and Swissmedic have granted the marketing authorization of nemolizumab for the treatment of both atopic dermatitis and prurigo nodularis in the UK and Switzerland, respectively. Specifically, the approvals are for nemolizumab’s subcutaneous use for the treatment of moderate-to-severe atopic dermatitis in combination with topical corticosteroids and/or calcineurin inhibitors in adults an
Kyocera Develops AI-powered 5G Virtualized Base Station for the Telecommunication Infrastructure Market18.2.2025 06:00:00 CET | Press release
Innovative solution for next-generation networks revolutionizes connectivity, increases fronthaul coverage Kyocera Corporation (President: Hideo Tanimoto) (TOKYO:6971) today announced that it has officially begun the full-scale development of an AI-powered 5G virtualized base station, with plans to commercialize the technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250217514858/en/ System Concept (Graphic: Business Wire) As digital transformation (DX) accelerates globally, 5G mobile networks have become a critical societal infrastructure. Kyocera is leveraging its proprietary, globally developed telecommunications and virtualization technologies to bring base station functionality to general-purpose servers using the NVIDIA GH200 Grace HopperTM Superchip. Using AI, Kyocera’s 5G virtualized base stations will enhance performance, reduce power consumption, and streamline both operations and maintenance. By offering th
Kyocera to Establish "O-RU Alliance" to Advance 5G Open RAN Deployment in Collaboration With Six Telecom Partners18.2.2025 06:00:00 CET | Press release
Kyocera Corporation (Kyoto, Japan; President: Hideo Tanimoto; "Kyocera") (TOKYO:6971) today announced that it will establish the "O-RU Alliance" on March 3, 2025, in collaboration with the six telecommunications companies listed below alphabetically: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250217720582/en/ O-RU Alliance (Graphic: Business Wire) Alpha Networks Inc. (Taiwan; Chairman/President/CEO: Wen Fang Huang) HFR, Inc. (Korea; CEO: Jong-Min Cheong) Microelectronics Technology Inc. (Taiwan; President and CEO: Eugene Wu) SOLiD Inc. (Korea; Vice Chairman and CEO: Seung Hee Lee) VVDN Technologies Pvt. Ltd (India; CEO: Puneet Agarwal) WNC (Wistron NeWeb Corporation) (Taiwan; Director, President and CEO: Jeffrey Gau) Working with alliance members, Kyocera will open its Central Unit / Distributed Unit platforms to promote the adoption of interoperable and flexible radio networks (Open RAN). The alliance plans to expand it
Azizi Developments Announces Sales Launch for Burj Azizi, the World’s Second-Tallest Tower at 725m18.2.2025 06:00:00 CET | Press release
Prices for the ultra-luxury, record-setting skyscraper start at AED 10,000 per square footBurj Azizi offers the only freehold residences on all of Dubai’s Sheikh Zayed RoadThe grand launch event will be held at Coca Cola Arena on the 18th of February 2025 Azizi Developments, a leading private developer in the UAE, will officially launch the sales of Burj Azizi, the world’s second-tallest tower, standing at an impressive 725 meters tall on a prime plot of land on Dubai’s Sheikh Zayed Road. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250218423172/en/ “Burj Azizi” (Photo: AETOSWire) The grand launch event will be held at the Coca Cola Arena, City Walk on February 18th, featuring a headline performance by American singer Jennifer Lopez (JLo) and will welcome over 15,000 attendees. Among the guests are government officials, media representatives, brokerage partners, banks and financial institutions, investors, high-profile inf
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom